Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer

Lung Cancer 2026

View at publisher
Authors: Jun‐Tao Lin, Jun‐Tao Lin, Xue-Ning Yang, Xue-Ning Yang, Xiang-Meng Li, Chao Zhang, Chao Zhang, Qiang Nie, Qiang Nie, Song Dong, Song Dong, Ben‐Yuan Jiang
+23 more Ben‐Yuan Jiang, Ri-Qiang Liao, Ri-Qiang Liao, Jing Kang, Jing Kang, Jia-Tao Zhang, Wen-Zhao Zhong, Jie Yang, Jie Yang, Sheng Zhang, Sheng Zhang, Jingyu Hou, Jingyu Hou, Rui Fu, Rui Fu, Zi-Hao Chen, Zi-Hao Chen, Zhen‐Bin Qiu, Zhen‐Bin Qiu, Hong-Hong Yan, Hong-Hong Yan, Yi‐Long Wu, Wen-Zhao Zhong
DOI: 10.1016/j.lungcan.2026.109389
Cited by: 2
References: 20

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Lung Cancer
Publisher
Elsevier BV
Volume
215
Pages
109389–109389
Publication date
28 March 2026
Language
EN